- Home
- BRX vs LEGN Comparison
BRX vs LEGN Comparison
Compare BRX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRX
- LEGN
- Stock Information
- Founded
- BRX 2011
- LEGN 2014
- Country
- BRX United States
- LEGN United States
- Employees
- BRX N/A
- LEGN N/A
- Industry
- BRX Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- BRX Real Estate
- LEGN Health Care
- Exchange
- BRX Nasdaq
- LEGN Nasdaq
- Market Cap
- BRX 8.0B
- LEGN 7.0B
- IPO Year
- BRX 2013
- LEGN 2020
- Fundamental
- Price
- BRX $25.17
- LEGN $31.78
- Analyst Decision
- BRX Buy
- LEGN Strong Buy
- Analyst Count
- BRX 13
- LEGN 13
- Target Price
- BRX $30.48
- LEGN $79.42
- AVG Volume (30 Days)
- BRX 2.2M
- LEGN 1.5M
- Earning Date
- BRX 04-28-2025
- LEGN 05-13-2025
- Dividend Yield
- BRX 4.57%
- LEGN N/A
- EPS Growth
- BRX 12.84
- LEGN N/A
- EPS
- BRX 1.05
- LEGN N/A
- Revenue
- BRX $1,302,325,000.00
- LEGN $627,241,000.00
- Revenue This Year
- BRX $5.21
- LEGN $65.96
- Revenue Next Year
- BRX $2.44
- LEGN $52.55
- P/E Ratio
- BRX $23.98
- LEGN N/A
- Revenue Growth
- BRX 3.87
- LEGN 119.97
- 52 Week Low
- BRX $21.32
- LEGN $29.27
- 52 Week High
- BRX $30.67
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- BRX 47.49
- LEGN 41.49
- Support Level
- BRX $24.87
- LEGN $30.25
- Resistance Level
- BRX $25.50
- LEGN $35.81
- Average True Range (ATR)
- BRX 0.53
- LEGN 1.45
- MACD
- BRX 0.01
- LEGN -0.18
- Stochastic Oscillator
- BRX 41.19
- LEGN 27.58
About BRX Brixmor Property Group Inc.
Brixmor Property Group Inc is a real estate investment trust based in the United States. The company owns and operates a portfolio of grocery-anchored community and neighborhood shopping centers across the United States. It leases its rentable areas to retailers, restaurants, theatres, entertainment venues, and fitness centers, with the company's tenants consisting of large department stores, discount retailers, and grocery stores. The company is an internally managed REIT. The company operates in Florida, Texas, California, New York, Pennsylvania, Illinois, New Jersey, Georgia, North Carolina, Michigan, Ohio and other states.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.